Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HPP737 in Healthy Volunteers
NCT04714294Phase 1Unknown
- Sponsor
- Newsoara Biopharma
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HPP737 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Newsoara Biopharma. Primary endpoint: Safety and Tolerability. Status: unknown.
02
Drugs
HPP737
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04714294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714294.